Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
IRWD Ironwood Pharmaceuticals, Inc. daily Stock Chart
IRWD [NASD]
Ironwood Pharmaceuticals, Inc.
Healthcare | Drugs - Generic | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.67 Insider Own4.80% Shs Outstand153.06M Perf Week9.59%
Market Cap2.33B Forward P/E- EPS next Y0.00 Insider Trans-6.69% Shs Float133.61M Perf Month13.43%
Income-254.80M PEG- EPS next Q-0.15 Inst Own- Short Float10.47% Perf Quarter32.87%
Sales310.20M P/S7.50 EPS this Y-39.20% Inst Trans-0.02% Short Ratio8.94 Perf Half Y-18.24%
Book/sh-1.29 P/B- EPS next Y100.00% ROA-46.10% Target Price15.05 Perf Year4.90%
Cash/sh1.05 P/C14.41 EPS next 5Y- ROE408.60% 52W Range9.07 - 21.20 Perf YTD46.72%
Dividend- P/FCF- EPS past 5Y-2.80% ROI-19.40% 52W High-28.30% Beta1.91
Dividend %- Quick Ratio2.20 Sales past 5Y14.70% Gross Margin93.50% 52W Low67.59% ATR0.78
Employees730 Current Ratio2.20 Sales Q/Q-24.30% Oper. Margin-71.60% RSI (14)65.70 Volatility7.10% 5.28%
OptionableYes Debt/Eq- EPS Q/Q-426.70% Profit Margin-82.10% Rel Volume1.44 Prev Close13.92
ShortableYes LT Debt/Eq- EarningsFeb 13 BMO Payout- Avg Volume1.57M Price15.20
Recom2.80 SMA2014.20% SMA5024.80% SMA200-5.91% Volume2,255,589 Change9.20%
Jan-24-19Upgrade JP Morgan Underweight → Neutral
Nov-07-18Downgrade JP Morgan Neutral → Underweight
Nov-07-18Downgrade Credit Suisse Outperform → Neutral
Jul-23-18Initiated H.C. Wainwright Sell $12.50
May-09-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-18Downgrade BofA/Merrill Buy → Underperform
Dec-06-17Downgrade Mizuho Buy → Neutral $16
Jul-21-17Downgrade JP Morgan Overweight → Neutral
May-03-17Initiated Wells Fargo Outperform
Apr-07-17Reiterated Mizuho Buy $21 → $22
Feb-22-17Reiterated Barclays Equal Weight $13 → $16
Nov-04-16Reiterated Mizuho Buy $19 → $20
Oct-24-16Reiterated Wedbush Neutral $10 → $13
Oct-10-16Reiterated Mizuho Buy $24 → $19
Sep-27-16Reiterated WallachBeth Hold $15 → $17
Jul-15-16Reiterated Mizuho Buy $16 → $24
May-10-16Reiterated Mizuho Buy $15 → $16
Apr-28-16Reiterated Wedbush Neutral $9 → $10
Mar-21-16Initiated Goldman Neutral
Feb-19-16Reiterated Wedbush Neutral $10 → $9
Feb-14-19 10:02AM  Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise Zacks -5.63%
07:27AM  Edited Transcript of IRWD earnings conference call or presentation 13-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-13-19 05:17PM  Why Ironwood's Shares Climbed 11.7% on Wednesday Motley Fool +11.66%
03:29PM  Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:50AM  Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:52AM  Ironwood: 4Q Earnings Snapshot Associated Press
07:00AM  Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update Business Wire
Feb-10-19 05:37PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Feb-06-19 10:30AM  Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline Zacks
Jan-29-19 10:43AM  Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid Zacks
Jan-28-19 05:00PM  Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call Business Wire
08:30AM  Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation Business Wire
Jan-25-19 08:10AM  Investor Expectations to Drive Momentum within Hercules Capital, Alexandria Real Estate Equities, Ironwood Pharmaceuticals, 22nd Century Group, BorgWarner, and Forestar Group Discovering Underlying Factors of Influence GlobeNewswire
Jan-24-19 10:44AM  Ironwood Commences Phase I Study on IW-6463 for CNS Disorders Zacks
08:00AM  Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation Business Wire
07:45AM  The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial Benzinga
Jan-23-19 04:01PM  Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials Business Wire
Jan-17-19 05:14AM  How to spot risky biotech companies and six to avoid now MarketWatch
Jan-16-19 10:05AM  Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C Zacks
Jan-15-19 08:00AM  Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C Business Wire +6.19%
Jan-07-19 09:50AM  Ironwood to Get New CEO, Current CEO to Head Latest Spinoff Zacks +5.09%
Jan-06-19 05:00PM  Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer Business Wire
Jan-04-19 07:08PM  Ironwood Pharmaceuticals Picks AstraZeneca Executive to Be Next CEO The Wall Street Journal +11.34%
12:29PM  Ironwood co-founder, CEO will step down to head new spinout American City Business Journals
12:05PM  Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation Business Wire
11:01AM  Ironwood Pharmaceuticals Picks AstraZeneca Executive to Be Next CEO The Wall Street Journal
Jan-03-19 10:27AM  Ironwood/Allergan Settle Linzess Patent Litigation With Mylan Zacks
Jan-02-19 05:00PM  Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference Business Wire
04:03PM  Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation Business Wire
Dec-18-18 11:56PM  Hedge Funds Are Betting On Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
Dec-14-18 04:44PM  Edited Transcript of IRWD earnings conference call or presentation 6-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Dec-11-18 01:51PM  Is Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Overpaying Its CEO? Simply Wall St.
Dec-06-18 09:30AM  Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report? Zacks
Nov-12-18 07:35AM  Research Report Identifies Ironwood Pharmaceuticals, The AES, Accuray, Ball, Park Hotels & Resorts, and NeoGenomics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -5.13%
Nov-08-18 04:05PM  Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference Business Wire
09:56AM  Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down Zacks
Nov-06-18 09:30AM  Ironwood Pharmaceuticals (IRWD) Reports Q3 Loss, Misses Revenue Estimates Zacks -9.55%
08:25AM  Ironwood: 3Q Earnings Snapshot Associated Press
08:09AM  Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update Business Wire
Oct-30-18 09:31PM  Novartis May Beat Ironwood Pharmaceuticals to the Punch Motley Fool -18.09%
Oct-25-18 05:00PM  Ironwood Pharmaceuticals to Host Third Quarter 2018 Investor Update Call Business Wire +5.61%
Oct-19-18 10:05AM  Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs Zacks
Oct-12-18 01:15PM  Ironwood Pharmaceuticals Incs (NASDAQ:IRWD) Profit Outlook Simply Wall St.
Oct-11-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within Ironwood Pharmaceuticals, Erie Indemnity, ONEOK, Sterling Construction, Colgate-Palmolive, and ON Semiconductor New Research Emphasizes Economic Growth GlobeNewswire
Oct-08-18 08:00AM  Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting Business Wire
Sep-14-18 11:14AM  Ironwood Stock Up, Heart Candidate Gets Fast Track Status Zacks
08:00AM  Today's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE
Sep-13-18 01:21PM  Ahead of split, Ironwood gets FDA fast track status for heart drug American City Business Journals
08:00AM  Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) Business Wire
Sep-05-18 10:41AM  Why Is Ironwood (IRWD) Up 0.9% Since Last Earnings Report? Zacks
Aug-28-18 04:05PM  Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences Business Wire
Aug-22-18 09:54AM  Ironwood's Linzess Gets Approval in Japan for New Indication Zacks
Aug-21-18 08:00AM  Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation Business Wire
Aug-17-18 11:40AM  Edited Transcript of IRWD earnings conference call or presentation 6-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-14-18 11:05AM  Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs Zacks
Aug-09-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Omnicom Group, Ironwood Pharmaceuticals, CorEnergy Infrastructure Trust, Cypress Semiconductor, Yum! Brands, and Zendesk New Research Emphasizes Economic Growth GlobeNewswire
Aug-07-18 10:24AM  Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down Zacks
Aug-06-18 09:20AM  Ironwood Pharmaceuticals (IRWD) Reports Q2 Loss, Lags Revenue Estimates Zacks
08:13AM  Ironwood: 2Q Earnings Snapshot Associated Press
08:00AM  Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update Business Wire
06:30AM  Ironwood Pharmaceuticals, Inc. Class A to Host Earnings Call ACCESSWIRE
Jul-23-18 04:01PM  Ironwood Pharmaceuticals to Host Second Quarter 2018 Investor Update Call Business Wire
Jul-19-18 07:50AM  Initiating Free Research Reports on Horizon Pharma and Three Other Healthcare Equities ACCESSWIRE
Jul-18-18 03:18PM  Alex Denner adds Ironwood Pharma and Medicines Co. to bes... CNBC Videos -5.55%
Jul-16-18 08:00AM  Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C) Business Wire
Jun-25-18 08:20AM  Today's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Aerie Pharmaceuticals ACCESSWIRE
Jun-23-18 08:00AM  Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Associations 78th Scientific Sessions Business Wire
Jun-22-18 10:08AM  Ironwood Initiates Phase III Studies on Reflux Candidate Zacks
Jun-21-18 04:05PM  Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease Business Wire
Jun-20-18 08:00AM  Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Associations 78th Scientific Sessions Business Wire
Jun-18-18 07:05AM  Free Research Reports on Ironwood Pharma and Three More Generic Drugs Stocks ACCESSWIRE
Jun-08-18 09:20AM  Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs Benzinga
Jun-07-18 04:05PM  Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease Business Wire
Jun-06-18 04:05PM  Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
Jun-05-18 04:05PM  Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week® 2018 Business Wire
May-31-18 11:28AM  Ironwood Pharmaceuticals (IRWD) Down 10.3% Since Earnings Report: Can It Rebound? Zacks +6.72%
11:00AM  Biotech activist Denner loses fight for Ironwood board seat American City Business Journals
09:30AM  Ironwood Pharmaceuticals Announces Results of 2018 Annual Meeting of Shareholders Business Wire
07:00AM  Sarissa Capital Issues Statement On Ironwood Pharmaceuticals PR Newswire
May-23-18 08:00AM  Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week® 2018 Business Wire
May-21-18 04:24PM  Wall Street Baffled Why Activist Sarissa Went Silent on Ironwood Bloomberg
May-14-18 07:30AM  Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees Business Wire
May-10-18 08:30AM  Today's Research Reports on Trending Tickers: Horizon Pharma and Ironwood Pharmaceuticals ACCESSWIRE
May-09-18 10:13AM  Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate Benzinga
08:30AM  Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value Business Wire
May-07-18 07:30AM  Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-03-18 04:05PM  Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation Business Wire
07:50AM  Blog Exposure - Ironwood to Separate Its Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business ACCESSWIRE
May-02-18 01:27PM  Edited Transcript of IRWD earnings conference call or presentation 1-May-18 12:30pm GMT Thomson Reuters StreetEvents
11:00AM  Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring Zacks
10:15AM  Ironwood slams Denner's bid for board seat as proxy fight looms American City Business Journals
08:00AM  Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders Business Wire
May-01-18 09:45PM  [$$] Ironwood Will Separate From Its Rare-Disease Drug Unit After Pressure The Wall Street Journal
04:01PM  Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action PR Newswire
03:18PM  Ironwood Pharma may satisfy activist Denner with split-up plan, but he still wants a board seat CNBC
10:08AM  Ironwood: 1Q Earnings Snapshot Associated Press
08:30AM  Cambridges Ironwood Pharmaceuticals to split into two businesses American City Business Journals
07:58AM  Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase (sGC) Business from Commercial and Gastrointestinal Business Business Wire
07:55AM  Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update Business Wire
Apr-17-18 04:01PM  Ironwood Pharmaceuticals to Host First Quarter 2018 Investor Update Call Business Wire
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and Nicox SA to generate various therapeutics for the treatment of certain ophthalmic conditions, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gilbert Halley EChief Legal OfficerJan 30Option Exercise4.8920,44999,996235,372Jan 31 05:35 PM
Hecht Peter MChief Executive OfficerJan 25Option Exercise4.8950,000244,5004,726,468Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 25Sale12.2329,551361,4094,696,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 24Option Exercise4.8930,000146,7004,726,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 24Sale12.7030,000381,0004,696,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 23Option Exercise4.8930,000146,7004,726,917Jan 25 06:24 PM
Hecht Peter MChief Executive OfficerJan 23Sale12.6630,000379,8004,696,917Jan 25 06:24 PM
OLANOFF LAWRENCE SDirectorDec 06Sale12.472,00024,94039,553Dec 10 04:37 PM
McHugh JulieDirectorDec 06Sale12.461,50018,69089,631Dec 10 04:56 PM
Consylman GinaChief Financial OfficerNov 09Sale11.811,35816,03896,361Nov 13 09:41 PM
Currie Mark GChief Scientific OfficerOct 05Option Exercise10.85116,6511,265,465146,775Oct 09 06:42 PM
Currie Mark GChief Scientific OfficerOct 05Sale17.53116,6512,044,89230,124Oct 09 06:42 PM
Currie Mark GChief Scientific OfficerOct 04Option Exercise10.85116,6501,265,454146,774Oct 09 06:42 PM
Currie Mark GChief Scientific OfficerOct 04Sale18.09116,6502,110,67830,124Oct 09 06:42 PM
McHugh JulieDirectorSep 05Sale19.101,50028,65091,131Sep 07 04:01 PM
OLANOFF LAWRENCE SDirectorSep 05Sale19.102,00038,20041,553Sep 07 04:01 PM
Currie Mark GChief Scientific OfficerAug 24Option Exercise4.9565,000321,783840,000Aug 28 04:03 PM
Currie Mark GChief Scientific OfficerAug 24Sale18.3965,0001,195,350775,000Aug 28 04:03 PM
Currie Mark GChief Scientific OfficerAug 23Option Exercise4.9565,000321,784840,000Aug 24 05:21 PM
Currie Mark GChief Scientific OfficerAug 23Sale18.3965,0001,195,350775,000Aug 24 05:21 PM
Currie Mark GChief Scientific OfficerAug 22Option Exercise4.9565,000321,784840,000Aug 24 05:21 PM
Currie Mark GChief Scientific OfficerAug 22Sale18.5165,0001,203,150775,000Aug 24 05:21 PM
Consylman GinaChief Financial OfficerAug 17Sale18.211883,42397,719Aug 21 04:57 PM
MCCOURT Thomas AChief Commercial OfficerJul 06Option Exercise5.4830,000164,40030,000Jul 10 05:18 PM
MCCOURT Thomas AChief Commercial OfficerJul 06Sale20.0030,000600,0000Jul 10 05:18 PM
Gilbert Halley EChief Legal OfficerJul 03Option Exercise4.8929,551144,50429,551Jul 05 04:12 PM
Gilbert Halley EChief Legal OfficerJul 03Sale19.7529,551583,6320Jul 05 04:12 PM
OLANOFF LAWRENCE SDirectorJun 05Sale17.622,00035,24043,553Jun 07 04:26 PM
McHugh JulieDirectorJun 05Sale17.621,50026,43092,631Jun 07 04:23 PM
McHugh JulieDirectorMar 05Sale14.061,50021,09077,908Mar 06 07:15 PM
OLANOFF LAWRENCE SDirectorMar 05Sale14.052,00028,10029,330Mar 06 07:17 PM
Gilbert Halley EChief Legal OfficerFeb 21Sale14.667,741113,48394,204Feb 22 06:04 PM
Currie Mark GChief Scientific OfficerFeb 21Sale14.661,63423,95418,124Feb 22 06:06 PM
MCCOURT Thomas AChief Commercial OfficerFeb 21Sale14.663,34349,00852,638Feb 22 06:05 PM
Consylman GinaChief Financial OfficerFeb 21Sale14.663,59452,68855,907Feb 22 06:02 PM
open in yahoo | open in reuters | open in google